💪Hims Launches Testosterone Therapy for 2.9M Customers
Hims enters the testosterone therapy market, but with a conservative approach
TL;DR
Hims, now serving 2.9 million customers, launches testosterone therapy for men, offering injectables and an oral pill. The service requires a video chat with a clinician and an at-home blood test.
Hims, a health platform with 2.9 million customers, has launched testosterone replacement therapy for men, offering two injectable treatments and an oral pill option. This service, which requires a video chat with a clinician and an at-home blood test, is a new phase for the company as it expands into men's health care. The oral pill option is sent to patients after they take a capillary blood test using a Tasso device. Hims competes with other online clinics but takes a more conservative approach, prescribing therapy based on medical history and lab results rather than as a lifestyle enhancer.
Key Points
Hims offers two injectable treatments and an oral pill for testosterone replacement therapy.
The oral pill option requires an at-home capillary blood test using a Tasso device.
Hims has grown from a startup to a publicly traded company with 2.9 million customers since 2017.
The service requires synchronous care, including a video chat with a clinician before prescribing.
Testosterone therapy can cause infertility and is not given to those trying to conceive.
Why It Matters
Hims' conservative approach to prescribing testosterone therapy is a significant shift in the market, focusing on medical necessity rather than lifestyle enhancement. This affects men seeking treatment for hypogonadism, who face a 35% increased risk of mortality. The service requires a video chat and an at-home blood test, ensuring proper diagnosis and treatment.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.
Join 3,569 builders reading daily.